Multiple treatments with human embryonic stem cell-derived mesenchymal progenitor cells preserved the fertility and ovarian function of perimenopausal mice undergoing natural aging.

"Declarations Ethics approval and consent to participateAll experiments using hESCs were performed with authorization from the Institutional Review Board for Human Research at CHA University, Seongnam, Korea (title of the approve project: Development of applying technology of homozygous somatic cell nuclear transferred-embryonic stem cells and their derivatives; name of the institutional approval committee: CHA University Institutional Review Board; Approval number and date: 1044308-201712-LR-051-03 (Jan. 24, 2019) and 1044308-201712-LR-051-04 (Feb. 11, 2020)). The experimental protocols were approved by the Institutional Animal Care and Use Committee of CHA University (title of the approval project: A study for improvement of ovarian reproductive function using human embryonic stem cell-derived mesenchymal progenitor cells; name of the institutional approval committee: CHA University IACUC; Approval number and date: IACUC 190050 (July 24, 2018), IACUC 190176 (July 31, 2019), and IACUC 200130 (Aug. 18, 2020)). Consent for publicationNot applicable. Competing interestsThe authors declare that they have no conflict of interest. Competing interests The authors declare that they have no conflict of interest."

"Funding This research was partly supported by the Korean Fund for Regenerative Medicine (KFRM, 23A0206L1) of MSICT and MHW, and the Bio & Medical Technology Development Program (2022M3A9I2082319) and Basic Science Research Program (2019R1A6A1A03032888) of NRF of Republic of Korea."